Infliximab therapy for patients with active and refractory spondyloarthropathies at the dose of 3 mg/kg: A 20-month open treatment

Journal of Clinical Rheumatology

Volumn 10, Issue 4, 2004, Pages 162-168

  Cherouvim, E P ^a   Zintzaras, E ^b   Boki, K A ^a   Moutsopoulos, H M ^a   Manoussakis, M N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

Ankylosing spondylitis; Infliximab; Psoriatic arthritis; Spondyloarthropathy; Treatment

Indexed keywords

INFLIXIMAB; METHOTREXATE;

ABSCESS; ADULT; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTICLE; CHILL; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; HYPOGLYCEMIA; MALE; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PHARYNGITIS; PILOT STUDY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RASH; RISK ASSESSMENT; SIDE EFFECT; SKIN INFECTION; SOMNOLENCE; SPONDYLOARTHROPATHY; TONSILLITIS; TOOTH DISEASE; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING;

EID: 4043066300     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000135551.47780.ba     Document Type: Article

References (41)

1. Khan MA. Spondyloarthropathies. Rheum Dis Clin North Am. 1992;18:1-282.
2. Arnett FC. The seronegative spondyloarthropathies. Bull Rheum Dis. 1987;37:1-12.
3. Ferraz MB, Tugwell P, Goldsmith CH, et al. Meta-analysis of sulfasalazine and ankylosing spondylitis. J Rheumatol. 1990;17:1482-1486.
4. Creemers MCW, Franssen MJAM, van der Putte LBA, et al. Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol. 1995;22:1104-1107.
5. Espinoza LR, Zakraoui L, Espinoza CG, et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol. 1992;12:872-877.
6. Steinsson K, Jonsdottir I, Valdimarsson H. Cyclosporin-A in psoriatic arthritis: an open study. Ann Rheum Dis. 1990;49:603-606.
7. Mazzanti G, Coloni L, Desabbata G, et al. Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis: a pilot study. Acta Derm Venereol Suppl (Stockm). 1994;186:116-117.
8. Farr M, Kittas GD, Waterhouse L, et al. Sulphasalazine in psoriatic arthritis: a double blind, placebo-controlled study. Br J Rheumatol. 1990;29:46-49.
9. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-TNF-α monoclonal antibody infliximab. Arthritis Rheum. 2000;43:1346-1352.
10. Van den Bosch, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of 3 infusions of chimeric monoclonal antibody to TNF-α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000;59:428-433.
11. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-390.
12. Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol. 2001;28:1605-1614.
13. Brandt J, Haibel H, Sieper J, et al. Infliximab treatment of severe ankylosing spondylitis: one-year follow-up (letter). Arthritis Rheum. 2001;44:2936-2937.
14. Van den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-α (Infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum. 2002;46:755-765.
15. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet. 2002;359:1187-1193.
16. Gorman J, Sack K, Davis J. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor-α. N Engl J Med. 2002;346:1349-1356.
17. Kruithof E, Van den Bosch F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis. 2002;61:207-212.
18. Maksymowych W, Jhangri G, Lambert R, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol. 2002;29:959-965.
19. Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology. 2002;41:1280-1285.
20. Antoni C, Dechant C, Hanns-Martin Lorenz P, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Care Res. 2002;47:506-512.
21. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38:499-505.
22. Grom AA, Murray KJ, Luyrink L, et al. Patterns of expression of TNF-α, TNF-β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum. 1996;39:1703-1710.
23. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998;25:1544-1552.
24. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of TNF-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997;24:518-523.
25. Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-α, IL-1β, IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994;33:927-931.
26. Toussirot E, Lafforgue P, Boucraut J, et al. Serum levels of IL-1β, TNF-α, soluble IL-2 receptor and soluble CD8 in seronegative spondyloarthropathies. Rheumatol Int. 1994;13:175-180.
27. Ettehadi P, Greaves MW, Wallach D, et al. Elevated TNF-α biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994;96:146-151.
28. Russell AS, Orozco JH, Maksymowych WP. The dosage of infliximab in the treatment of ankylosing spondylitis: dollars and sense. Clin Exp Rheumatol. 2002;28(suppl):S135-136.
29. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-368.
30. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286-2291.
31. Emery P, Reginster JY, Appelboom T, et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford). 2001;40:699-702.
32. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281-2285.
33. Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis: the Bath Ankylosing Spondylitis Metrology Index. J Rheumatol. 1994;21:1694-1698.
34. Daltroy L, Larson M, Roberts N, et al. A modification of the Health Assessment Questionnaire for the Spondyloarthropathies. J Rheumatol. 1990;17:946-950.
35. Van Tubergen A, van der Heijde D, Anderson J, et al. Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis. 2003;62:215-221.
36. Fredricksson T, Peterson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238-244.
37. Pocock SJ. Clinical Trials. Chichester, England: Wiley; 1990.
38. St. Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Arthritis Rheum. 2002;46:1451-1459.
39. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med. 2001;345:1098-1104.
40. Smith J, Levinson R, Holland G, et al. Differential efficacy of tumor necrosis inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252-257.
41. Kaipiainen-Seppänen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumor necrosis factor-α inhibitors. Ann Rheum Dis. 2003;62:88-89.